TZALI Cnaani, CEO, Founder of Carmel Diagnostics on IVF pregnancy and the impact of Covid-19.
First of all, how are you and your family doing?
TZALI Cnaani: Thank you. We are all vaccinated and recovered from the easy corona.
Tell us about you, your career, and how you founded Carmel Diagnostics.
TZALI Cnaani: I have a long career in technology companies. I spent years in the software industry (mainly MIS), then went to management in computer communications companies, ran for 5 years a world-leading company in computerized milking systems – dairy management and then ran Lumitest, followed by Carmel diagnostics that went into the shoes of Lumitest. Formed Carmel after acquiring the assets of Lumitest
How does Carmel Diagnostics market its product/services online?
TZALI Cnaani: We have a website and record on LinkedIn.
How the coronavirus pandemic affects your business, and how did you get through it?
TZALI Cnaani: Corona caused a substantial delay in our activity. We focused on the activity in China which was and is still blocked. We registered a Chinese subsidiary in 02-2020 and could not operate it. Even now, the lockdown in Shanghai stops potential partners from proceeding in contact, and the connection with international partners was slowed.
What specific tools, software, and management skills are you using to manage your online marketing?
TZALI Cnaani: Actually, our online marketing is limited. We focus on fundraising and looking for distributors that require direct contact and fewer “marketing” activities.
Who are your competitors? And how do you plan to stay in the game?
TZALI Cnaani: Our main competitors are companies providing time-lapse systems, such as Vitrolife, Genea, and Esco, as well as start-ups building AI systems for IVF. We plan to show our superiority in studies and the actual use of the clinics.